SCHEMBL5409541

SCHEMBL5409541

C=CCNC(=O)c1ccccc1-c1ccccc1C(=O)N(CCC(=O)O)CCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.56
HPGD P15428 5/20 0.46
CYP1A2 P05177 2/20 0.46
ALDH1A1 P00352 5/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
CHRNB2 P17787 1/20 0.40
CHRNB4 P30926 1/20 0.40
CHRNA3 P32297 1/20 0.40
CHRNA4 P43681 1/20 0.40
TP53 P04637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ALOX15 P16050 1/20 0.40
CYP3A4 P08684 2/20 0.39
MLNR O43193 1/20 0.39
NPC1 O15118 1/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5405921 0.94 MAPT (0.55) MAPTHPGDCYP1A2ALDH1A1LMNA
SCHEMBL5396800 0.93 MAPT (0.48) MAPTHPGDCYP1A2ALDH1A1LMNA
SCHEMBL5404013 0.93 MAPT (0.48) MAPTHPGDCYP1A2ALDH1A1LMNA
SCHEMBL5402674 0.90 KMT2A (0.48) MAPTHPGDCYP1A2ALDH1A1TSHR
SCHEMBL5409220 0.90 TDP1 (0.48) MAPTALDH1A1LMNAGAAKMT2A
SCHEMBL5405631 0.90 MAPT (0.51) MAPTHPGDCYP1A2ALDH1A1LMNA
SCHEMBL5394820 0.89 CA1 (0.51) MAPTALDH1A1LMNA
SCHEMBL5402238 0.88 MAPT (0.44) MAPTHPGDCYP1A2ALDH1A1LMNA
SCHEMBL5406651 0.87 RAB9A (0.53) MAPTHPGDALDH1A1HDAC1HDAC6
SCHEMBL5409780 0.87 CHRNB2 (0.56) HPGDALDH1A1LMNAGAACHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB MAPT 457/4885HPGD 1078/4885CYP1A2 2649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.